Ernexa Therapeutics Inc. ERNA
Ernexa Therapeutics Inc. (Nasdaq: ERNA) is an oncology drug developer. Its lead program, ERNA-101, is in Pre-clinical for platinum-resistant ovarian cancer. Its next catalyst on record is ERNA-101: IND submission (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: ERNA-101 — IND submission (Q4 2026). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| ERNA-101 | platinum-resistant ovarian cancer | cell therapy | Pre-clinical |
| ERNA-201 | autoimmune diseases (collagen-induced arthritis model tested) | cell therapy | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other pre-clinical oncology companies
- Legend Biotech Corp LEGN
- Veracyte, Inc. VCYT
- Indaptus Therapeutics, Inc. INDP
- SL Science Holding Ltd SLBT
- YD Bio Ltd YDES
- OnKure Therapeutics, Inc. OKUR
- Boundless Bio, Inc. BOLD
- NextCure, Inc. NXTC
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.